This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept
David King, JD

David King, JD

Operating Partner, Pritzker Private Capital / United States

David King, JD, is Operating Partner at Pritzker Private Capital leading the firm’s activities in the Healthcare sector. Prior to joining Pritzker Private Capital, Mr. King was most recently executive chairman and CEO of LabCorp (NYSE: LH). He is a respected senior healthcare leader who operates with a strong emphasis on deeply understanding the healthcare industry, strategic planning, “playing the long game,” and staying ahead of rapidly evolving industry trends and challenges. Under his leadership, LabCorp transformed from a pure-play U.S. testing laboratory into a leading global life sciences company — tripling in size through a combination of organic growth and strategic acquisitions, entering the Fortune 500, and being named to Fortune’s List of World’s Most Admired Companies. It is now the world’s largest clinical laboratory and second-largest drug development business.

Mr. King was appointed in 2017 to the advisory board for Duke University’s Robert J. Margolis, MD, Center for Health Policy. He previously served on the board of Cardinal Health (NYSE: CAH), a Fortune 20 healthcare company, Elon University and the American Clinical Laboratory Association, where he served as board chair from 2010 to 2014. Mr. King is also on the board of The Emily K Center, a college-readiness center that Duke Men's Basketball Coach Mike Krzyzewski founded to prepare high school students in Durham, North Carolina for college and leadership.

Mr. King holds a bachelor’s degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the University of Pennsylvania Law School.

From 2018 until January 2022, Mr. King served as Board Chair. He is a member of the Executive Committee, Audit and Risk Committee, and Compensation Committee.

Appointed to the board: December 2013